Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)

Inclusion Criteria: * Histologically documented Stage I-IV or recurrent uterine or ovarian carcinosarcoma not amenable to surgery or radiotherapy * No more than 2 previous chemotherapy lines * PS 0-2 (ECOG) * Age\> 18 * Measurable disease * Life expectancy of at least 3 months * Adequate organ functions: * Hematopoietic; Absolute neutrophil count ≥ 1,500/mm\^3; Platelet count ≥ 100,000/mm\^3; Hemoglobin ≥ 9 g/dL Hepatic; AST and ALT ≤ 1.5 times upper limit of normal (ULN)\*; Protocol Version 1.0\_05.09.2016 6 Alkaline phosphatase ≤ 2.5 times ULN\*; Bilirubin ≤ 1.5 times ULN NOTE: \* ≤ 3 times ULN if liver metastases are present Renal; Creatinine Clearance ≥ 45 mL/min or Serum Creatinine ≤1.5 x ULN Serum Albumin \>3.0 g/dL * Previous Brachytherapy treatment for uterine carcinosarcoma is allowed * No other invasive malignancy within the past 3 years except non-melanoma skin cancer * Written Informed Consent Exclusion Criteria: * More than 2 previous chemotherapy lines * Single tumor lesion inside a previous irradiated filed * Pregnant (potentially fertile patients must be not in pregnancy during and for at least 3 months after study participation and must have a negative serum pregnancy test) * Active infection requiring antibiotics * Symptomatic peripheral neuropathy \> grade 2 according to the NCI Common Toxicity Criteria. * Congestive heart failure or angina pectoris even if it is medically controlled. Previous history of myocardial infarction within 1 year from study entry, uncontrolled high risk hypertension or arrhythmia. * Unstable or severe intercurrent medical condition that, in the opinion of the investigator, might interfere with achievement of study objectives * Psychological or sociological conditions, addictive disorders, or family problems, which would preclude compliance with the protocol